Expert Interview
Discussing Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and the Potential of Cytokinetics' aficamten in ACACIA-HCM, a Pivotal Phase 3 Clinical Trial
Ticker(s): CYTKInstitution: The Christ Hospital
Advanced Heart Failure & Transplant Cardiologist at The Christ Hospital in Cinncinnati, OH
Manages 500+ patients with Hypertrophic Cardiomyopathy
Co-Director of the Hypertrophic Cardiomyopathy Clinic and serves as a Principal Investigator on numerous HCM-related trials
How many nHCM patients do you manage?
Added By: wilson_adminWhat is the outlook for ACACIA-HCM?
Added By: wilson_adminHow quickly would this be adopted if aficamten was approved for nHCM?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
